X0508 4 2023-11-16 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 1 1 0 0 CEO and President 1 Common Stock 2023-11-16 4 M 0 102249 A 4915446 D Common Stock 2023-11-16 4 F 0 50697 28.86 D 4864749 D Common Stock 2023-11-17 4 S 0 51352 29.0958 D 4813397 D Common Stock 2023-11-17 4 S 0 200 29.55 D 4813197 D Common Stock 1012722 I See Footnote Common Stock 995686 I See Footnote Restricted Stock Units 2023-11-16 4 M 0 5129 0.00 D Common Stock 5129 10259 D Restricted Stock Units 2023-11-16 4 M 0 2394 0.00 D Common Stock 2394 11971 D Restricted Stock Units 2023-11-16 4 M 0 61182 0.00 D Common Stock 61182 61182 D Restricted Stock Units 2023-11-16 4 M 0 33544 0.00 D Common Stock 33544 436072 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 102,249 shares of Common Stock underlying the Reporting Person's RSUs. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2022. Represents the weighted average sale price of the shares sold from $28.55 to $29.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. /s/ Brian C. Stephenson, Attorney-in-Fact 2023-11-20